Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX) from its SEC filings: 2025 revenue $0 (-100% vs the year before), free cash flow -$123.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Revenue growth | -100% |
| Net income | -$144.7 million |
| Free cash flow | -$123.5 million |
| Diluted EPS | $-1.53 |
| Latest quarter (Q3 2025 (calendar)) revenue vs a year earlier | -100% |
| Cash | $49.3 million |
| Share count, 1 year | +25% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.